Aib substitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
===== The maxillary division innervation ===== Maxillary nerve – conveys sensation to the upper jaw and the face. Infraorbital nerve – conveys sensation to the area from below the eye socket to the external nares (nostrils). Zygomatic nerve – through the zygomatic bone and the zygomatic arch, conveys sensation to the cheekbone areas. Superior posterior dental nerve – sensation in the teeth and the gums. Superior anterior dental nerve – mediates the sneeze reflex. Sphenopalatine nerve – divides into the lateral branch and the septal branch, and conveys sensation from the rear and the central regions of the nasal cavity.
=== Research === In AI safety, local solutions focus on individual AI systems, ensuring they are safe and beneficial, while global solutions seek to implement safety measures for all AI systems across various jurisdictions. AI safety governance research ranges from foundational investigations into the potential impacts of AI to specific applications. On the foundational side, researchers have argued that AI could transform many aspects of society due to its broad applicability, comparing it to electricity and the steam engine. Some work has focused on anticipating specific risks that may arise from these impacts – for example, risks from mass unemployment, weaponization, disinformation, surveillance, and the concentration of power. Other work explores underlying risk factors such as the difficulty of monitoring the rapidly evolving AI industry, the availability of AI models, and 'race to the bottom' dynamics. Allan Dafoe, the head of longterm governance and strategy at DeepMind has emphasized the dangers of racing and the potential need for cooperation: "it may be close to a necessary and sufficient condition for AI safety and alignment that there be a high degree of caution prior to deploying advanced powerful systems; however, if actors are competing in a domain with large returns to first-movers or relative advantage, then they will be pressured to choose a sub-optimal level of caution". A research stream focuses on developing approaches, frameworks, and methods to assess AI accountability, guiding and promoting audits of AI-based systems.
No charges have been brought against the contractor because he does not fall under military jurisdiction; it is questionable whether any charges will or even can be brought against him. Donald Rumsfeld had said that army and government had only been informed in January and not in detail. On January 16, 2004, a press release was issued by the United States Central Command (CENTCOM) stating that an investigation had been initiated in response to allegations of detainee abuse at an unspecified detention facility (now known to be Abu Ghraib prison). In March 2004, 6 soldiers in Abu Ghraib were charged with dereliction of duty, cruelty and maltreatment, and sexual abuse. 17 others were suspended from duty, including the seven U.S. officers who ran the prison. Also recommended for discipline was Brig. Gen Janis Karpinski, the commander of the 800th brigade. The Red Cross, which had access to these prisons, has stated that the instances of torture were not aberrations but were systemic. Some officers have attempted to defend themselves by saying that they were only doing their duty. In response to ongoing complaints, the US military initiated a program to reform the internment and treatment systems. The reforms are expected to increase safeguards for prisoners' rights, to ensure each prisoner receives a copy of their internment order, and has their charges explained to them within 72 hours. They additionally plan to publicly post information about detainees so that family members can know what happened to their loved ones. Reforms were made in March 2004.
Carbamazepine is typically used for the treatment of seizure disorders and neuropathic pain. It is used off-label as a second-line treatment for bipolar disorder and in combination with an antipsychotic in some cases of schizophrenia when treatment with a conventional antipsychotic alone has failed. However, evidence does not support its usage for schizophrenia. It is not effective for absence seizures or myoclonic seizures. Although carbamazepine may have a similar effectiveness (as measured by people continuing to use a medication) and efficacy (as measured by the medicine reducing seizure recurrence and improving remission) when compared to phenytoin and valproate, it is not well-researched which medication is most helpful for people with newly-onset seizures. In the United States, carbamazepine is indicated for the treatment of epilepsy (including partial seizures, generalized tonic-clonic seizures and mixed seizures), and trigeminal neuralgia. Carbamazepine is the only medication that is approved by the Food and Drug Administration for the treatment of trigeminal neuralgia. As of 2014, a controlled release formulation was available for which there is tentative evidence showing fewer side effects and unclear evidence with regard to whether there is a difference in efficacy. In 2016, the FDA approved an intravenous formulation of carbamazepine, also granting it orphan drug status under the trade name Carnexiv, as a short-term replacement therapy for oral carbamazepine in adults with specific types of seizure disorders, who are unable to tolerate the oral formulation.
Sources: en.wikipedia.org
Though originally planned to be presented at a ceremony at the Queen Elizabeth Hall in London, the event was instead presented as a live stream on 2 April 2020 due to concern over the COVID-19 pandemic.
Also in 1894, the civil parishes within the Wilmslow district were united into a single parish of Wilmslow, and Styal was made a separate parish. On 1 April 1936, the urban district of Wilmslow was enlarged to take in Handforth and Styal. Wilmslow Urban District Council was granted a coat of arms on 21 June 1951. Wilmslow Urban District was abolished in 1974 under the Local Government Act 1972. As part of those reforms, the area had been considered for possible inclusion within Greater Manchester, but it was ultimately decided to place it in the borough of Macclesfield. No successor parish was created for the former urban district and so it became unparished, being directly administered by Macclesfield Borough Council. In 2009, Cheshire East Council was created, taking over the functions of the borough council and Cheshire County Council, which were both abolished. In 2011, the area of the former Wilmslow Urban District was split into three new parishes called Wilmslow, Handforth, and Styal.
== Function == Manganese is a component of some enzymes (such as arginase) and stimulates the development and activity of other enzymes. Manganese superoxide dismutase (MnSOD) is the principal antioxidant in mitochondria. Several enzymes activated by manganese contribute to the metabolism of carbohydrates, amino acids, and cholesterol. A deficiency of manganese causes skeletal deformation in animals and inhibits the production of collagen in wound healing.
Sources: en.wikipedia.org
== Drug development risks == Risks that could affect the further development of tecemotide published in the annual reports of Oncothyreon (grantor of the license) and Merck KGaA (license holder; responsible for clinical development, marketing and manufacturing) are listed in the following sections.
==== Phase transitions ==== At a pressure of one atmosphere (atm), ice melts or water freezes (solidifies) at 0 °C (32 °F) and water boils or vapor condenses at 100 °C (212 °F). However, even below the boiling point, water can change to vapor at its surface by evaporation (vaporization throughout the liquid is known as boiling). Sublimation and deposition also occur on surfaces. For example, frost is deposited on cold surfaces while snowflakes form by deposition on an aerosol particle or ice nucleus. In the process of freeze-drying, a food is frozen and then stored at low pressure so the ice on its surface sublimates. The melting and boiling points depend on pressure. A good approximation for the rate of change of the melting temperature with pressure is given by the Clausius–Clapeyron relation:
Tendinitis is a type of overuse injury to the tendons, which demonstrates signs of inflammation of tendons around a joint. Tendinitis is the most common cause of shoulder pain and also leg pain . Tendinitis occurs when there is repetitive stress on the subacromial bursa, which causes the bones to make contact with the tendons and irritate them.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.